The effect of two synthetic lipid A partial structures, compound 406 (or LA-14-PP, identical in structure to the lipid A precursor, known as Ia or IVa) and compound 401 (lipid X), on the in vitro modulation of endotoxin (lipopolysaccharide)-induced interleukin-6 production by human blood mononuclear cells was investigated. Lipopolysaccharide of Salmonella abortus equi and synthetic Escherichia coli-type lipid A (compound 506, or LA-15-PP) had potent interleukin-6-inducing capacities. The maximum release of interleukin-6 was found after stimulation with 1 to 10 ng of lipopolysaccharide or 10 to 100 ng of synthetic E. coli-type lipid A per ml. Both synthetic lipid A partial structures (compounds 406 and 401) failed to induce interleukin-6 release. However, they inhibited lipopolysaccharide-or lipid A-induced interleukin-6 production in a dose-dependent manner. Inhibition was found not only in mononuclear cells but also in purified monocytes and was not due to a shift in the kinetics of cytokine production. Suppression was manifested in the early stage of interleukin-6 production. Inhibition was also found in the presence of recombinant gamma interferon, indicating that compound 406 and recombinant gamma interferon act in different, independent pathways. Our data, therefore, indicate that the inhibition of interleukin-6 production by lipid A partial structures may help elucidate the mechanism of interaction of the lipid A component of lipopolysaccharide with immune cells in the inflammatory reaction during gram-negative infection.
Cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor (TNF), play an important role in inflammatory reactions and immunological functions induced by bacterial lipopolysaccharide (LPS) (endotoxin) during infection with gram-negative bacteria (4, 8) . The multiple inflammatory activities of these cytokines in the pathogenesis of certain diseases have been reported (2, 18, 22) . The symptoms observed during gram-negative infection, such as fever, acute-phase response, leukocytosis, and septic shock, are considered to be due mainly to the diverse activities of these cytokines released from immune cells after exposure to LPS and other bacterial products (8, 42, 44) . Recently, IL-6 has also been implicated in the pathophysiology of bacterial infections (16, 20, 46) . Clinically, elevated levels of IL-6 in various biological fluids have been found in patients with infectious diseases such as meningococcal meningitis and septic shock (8, 13, 22, 24) . It was shown that high levels of IL-6 in serum coexisted with TNF, IL-1, and LPS in the systemic circulation during the initial phase of bacterial septic shock and were directly associated with a fatal outcome (44) . It was also reported that clinical signs of endotoxemia were correlated with high levels of IL-6 in serum when TNF production was selectively inhibited (48) . Moreover, it was shown that anti-IL-6 monoclonal antibody pretreatment of mice subsequently challenged intraperitoneally with lethal doses of Escherichia coli or intravenously with lethal doses of TNF protected mice from death caused by these treatments (12) . Although the precise role of remains largely unknown, accumulated evidence strongly * Corresponding author.
indicates that IL-6 may be an important factor in the development of the lethal shock caused by the combination of TNF and IL-1 induced by bacterial LPS (38) . Therefore, the abnormal expression and dysregulation of IL-6 in certain disorders may be typical features of this cytokine directly related to pathogenesis (20, 46) . Two lipid A partial structures, lipid A precursor Ia and lipid X, were initially reported to be less active in vivo and in vitro than other bioactive lipid A preparations in endotoxic reactions, including pyrogenicity, local Shwartzman reaction, lethal toxicity in mice, mitogenicity for mouse B lymphocytes, and complement activation (3, 7, 14, 26) . Subsequently, both synthetic substances were used in vitro, with human peripheral blood mononuclear cells (PBMC) and monocytes to evaluate their cytokine-inducing capacities. We found that compound 406 (synthetic lipid A precursor Ta) and compound 401 (synthetic lipid X) were inactive in the induction of IL-1 and TNF release (10, 29, 32) but that they could block LPS-or lipid A-induced production of cytokines such as IL-1 and TNF (31, 45) . Similar results were found when natural lipid A partial structures, such as lipid IVa, were used (27) . The observations that both lipid A partial structures largely lacked cytokine-inducing capacities in human monocytes but could modulate cytokine release can be regarded as a potential step forward in the use of such derivatives as immunomodulators in vivo.
Despite the fact that IL-6 is regulated, at least in part, independently of IL-1 and TNF (48) and is the most important monokine released during endotoxic reactions, it is necessary to investigate the effect of compounds 406 and 401 on LPS-induced IL-6 production. In the present study, we demonstrate that both compounds 406 and 401 are also inactive in stimulating IL-6 release by human PBMC or monocytes. Apart from their suppressive activities on IL-1 and TNF production (27, 31, 40, 45) , synthetic lipid A partial structures also inhibit IL-6 release induced by wild-type LPS and synthetic lipid A. Monocytes may be one of the target cells influenced by lipid A partial structures in the production of IL-6 induced by LPS and lipid A. On the basis of the biochemical and immunological properties of synthetic lipid A partial structures, we postulate that these structures prevent the effective action of LPS required for the induction of IL-6 in immune cells and have the potential to be used for the modulation of abnormal immunological reactions in certain diseases (11) .
MATERIALS AND METHODS LPS, synthetic lipid A, and partial structures. LPS was extracted from Salmonella abortus equi and purified by the phenol-chloroform-ethanol method as described by Galanos et al. (15) . Compound 506 (synthetic hexaacyl E. coli-type lipid A) was synthesized as described previously (25) , is composed of a bisphosphorylated glucosamine disaccharide with six acyl residues, and corresponds structurally to free lipid A prepared from LPS of the E. coli Re mutant strain F515 (25) . Compound 406 (synthetic tetraacyl lipid A precursor Ia) represents a partial structure of compound 506 lacking dodecanoic and tetradecanoic acids and was synthesized as described previously (14) . Compound 401 (synthetic lipid X), representing a 1-phosphorylated glucosamine residue carrying two molecules of (R)-3-hydroxytetradecanoic acids, was synthesized as described previously (28) . It was solubilized as described elsewhere (29) . In brief, the dry substance was wetted with ethanol (10 FLl/mg of compound 401) and sonicated for 1 min in an ultrasound water bath, ensuring that the temperature was below 10°C. During further sonification, 1 ml of pyrogen-free phosphate-buffered saline (PBS) was added dropwise. Sonication was continued until a slightly opalescent solution was obtained; this solution was filtered (0.45-,um-pore-size filter) and kept at 4°C. The other substances were treated and stored in the same way. The chemical structures of the synthetic compounds are shown in Fig. 1 .
Cytokines and antibodies. Human recombinant IL-6 (rIL-6) exhibiting a specific activity of 107 U/mg of protein was purchased from Genzyme Fine Chemicals (Boston, Mass.). Human recombinant gamma interferon (rIFN--y) was kindly provided by Karl Thomae GmbH (Biberach, Germany); the specific activity was 4 x 107 U/mg of protein.
A mouse monoclonal antibody against human IL-6 was kindly provided by F. di Padova (Sandoz AG, Basel, Switzerland). A rabbit polyclonal antiserum against human IL-6 was purchased from Genzyme Fine Chemicals.
Biological reagents. Mycobacterium bovis BCG was provided by Institut Merieux GmbH (Leimen, Germany). Staphylococcus aureus Cowan 1 (Pansorbin) was purchased from Calbiochem GmbH (Frankfurt am Main, Germany).
PBMC separation and preparation of monocytes. Samples of blood from various healthy donors were collected in heparin at 10 U/ml. PBMC were separated by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation as described previously (6) . After three washes with cold Hanks solution at 4°C, the PBMC were suspended in serum-free RPMI 1640 medium supplemented with 100 U of penicillin and 100 ,ug of streptomycin per ml (RPMI 1640-M). For the preparation of monocytes, PBMC at 2 x 106/ml were placed in a plastic petri dish and incubated at 37°C Bioassay for IL-6 activity. IL-6 activity was determined by using an IL-6-dependent B9.9-3A4 cell proliferation assay but with methylthiazol tetrazolium bromide (MTT) for detection (1, 35) . The assay was carried out in 96-well flatbottom microtiter plates at 200 ,ul per well. The number of B9.9-3A4 cells in each well was 104. The samples were titrated at various dilutions in triplicate. A standard preparation of rIL-6 (150 U/ml) was used as a positive control. After incubation at 37°C in 5% CO2 for 56 h, 10 ,ul of MTT solution (5 mg/ml in PBS [pH 7.4]) was added to each well. Cells were cultured for another 3 h at 37°C. The MTT reaction was stopped by the addition of 100 ,l1 of acidified isopropanol (0.04 N HCl in isopropanol). The dark blue formazan products were dissolved by vigorous mixing with a microplate shaker and measured at 550 nm with a microplate enzyme-linked immunosorbent assay (ELISA) reader (MR 700; Dynatech, Denkendorf, Germany). IL-6 activity was calculated by probit analysis as described elsewhere for IL-2 (17).
Sandwich ELISA for IL-6. The method used for the detection of IL-6 was based on a detection method described for IL-2 (5), with slight modifications. In brief, Microtest III plates were coated with 100 ,ul of mouse monoclonal anti-IL-6 antibody per ml and incubated at 4°C overnight, and unspecific binding was blocked by the addition of 150 pul of 1% bovine serum albumin in PBS per well as a blocking solution. Samples and a standard preparation of rIL-6 were diluted in sample buffer (1% bovine serum albumin and 1% EDTA in PBS). Wells containing sample buffer only were used as negative controls. The plates were incubated at room temperature for 4 h. A rabbit polyclonal anti-IL-6 antibody serving as a detecting antibody was added to each well, and the plates were incubated for another 2 h. Between each step, the wells were washed three times with washing buffer (0.1% Tween 20 in PBS). The reaction was developed with peroxidase-conjugated donkey anti-rabbit immunoglobulin G antibody (Dianova, Hamburg, Germany IL-6 molecules were calculated by comparison with the defined standard preparation of rIL-6.
Statistical analysis. All experiments were performed with three different donors. Samples were tested in triplicate. Each point in the figures represents the mean number for three wells. The significance of differences between groups was calculated by Student's t test. A P value of 0.05 was used as the limit of statistical significance. RESULTS IL-6 activity induced by S. abortus equi LPS and compounds 506, 406, and 401. In preliminary experiments, PBMC from several healthy donors were stimulated to produce IL-6 by different concentrations of S. abortus equi LPS or compound 506, 406, or 401. S. abortus equi LPS could induce high amounts of IL-6 activity in supernatants (Fig. 2) . The minimal concentration at which we could detect IL-6 release was 10 pg of S. abortus equi LPS per ml. In comparison with S. abortus equi LPS, compound 506 was less active in the induction of IL-6 in PBMC (Fig. 2) . The dose-response curves indicated that the maximal release of IL-6 in PBMC was found after stimulation with 1 to 10 ng of S. abortus equi LPS or 10 to 100 ng of compound 506 per ml and that the amount of IL-6 produced after LPS stimulation was about four-or fivefold higher than that produced after compound 506 stimulation. In contrast, compound 406 did not induce IL-6 release from PBMC, even when high concentrations, up to 2 ,ug/ml, were used (Fig. 2) Effect of compound 406 on S. abortus equi LPS-induced IL-6 release. PBMC from six individual donors were stimulated with S. abortus equi LPS (1 ng/ml) in the presence or absence of compound 406 (1,000 ng/ml). PBMC stimulated with S. abortus equi LPS showed a strong release of IL-6 after 20 h of incubation (Table 1) . Control cultures without a stimulus showed mostly negative values, except for those for two donors showing a spontaneous release of IL-6 at low levels. Similarly, PBMC incubated with compound 406 also did not release IL-6. However, although not bioactive by itself, compound 406 significantly inhibited S. abortus equi LPS-induced IL-6 release in all six experiments. The inhibition ranged from 90 to 99%. In addition, we found by trypan blue staining that compound 406 at concentrations of up to 2 ,ug/ml had no demonstrable effect on the survival of either S. abortus equi LPS-stimulated or nonstimulated PBMC after 20 h of culturing (data not shown).
Dose-dependent inhibition of IL-6 release by lipid A partial structures. PBMC were stimulated with S. abortus equi LPS (1 ng/ml) and cultured in the presence of various concentrations of compound 406 or 401. Typical results (Fig. 3) (Fig. 4) compound 406 served as controls. For the various IL-6 inducers used, IL-6 release induced by BCG or S. aureus Cowan 1 was not influenced, whereas IL-6 release induced by S. abortus equi LPS was blocked by the addition of compound 406 (Table 2) . Modulation by rIFN-,y of lipid A partial structure-mediated IL-6 inhibition. We tested whether rIFN--y was capable of counteracting the inhibitory action of lipid A partial structures on LPS-induced IL-6 release. PBMC were stimulated with S. abortus equi LPS (1 ng/ml) together with different amounts of compound 406 or 401. Human rIFN-y (100 U/ml) was added simultaneously. Cells stimulated with LPS plus rIFN--y produced higher amounts of IL-6 than did those stimulated with LPS alone, whereas compound 406 or 401 was not able to induce IL-6 release, even in the presence of rIFN--y (Table 3) . When the modulating effect of rIFN-y on lipid A partial structure-mediated inhibition was investigated, we we and others found modulating activities of defined structures of lipid A for cytokine production induced by LPS in vitro, suggesting that inactive lipid A partial structures may serve as antagonists against LPS-mediated inflammatory reactions in vivo (11, 19, 27, 36, 45) . In the present study, we focused our experimental approaches on the immunostimulatory effects of LPS and synthetic lipid A on the induction of IL-6 and its regulation at the cellular level by synthetic lipid A partial structures, including compounds 406 and 401.
LPS and synthetic E. coli-type lipid A (compound 506)
were potent inducers of IL-6 release in PBMC and monocytes. The production of IL-6, as determined by IL-6-dependent B9.9-3A4 cell proliferation, was detectable at S. abortus equi LPS concentrations as low as 10 pg/ml. Although compound 506 was active in inducing the production of IL-6, it was not as potent as S. abortus equi LPS. In terms (10, 11, 31, 32) . We here further confirmed that both compounds 406 and 401 also had no stimulatory activity in the induction of IL-6 in human PBMC and monocytes in vitro.
On the basis of the structural similarities between lipid A (29) and other LPS-related reactions (19) . In our experiments, the diminished IL-6 bioactivities in the culture supernatants after the addition of compound 406 were correlated with the decreased quantities of IL-6 molecules in the supernatants, as measured by a sandwich ELISA. This result implies that the inhibition of IL-6 release mediated by lipid A partial structures was indeed caused by a change in the release of IL-6 peptide molecules. Further investigations of the kinetics of LPS-induced IL-6 production indicated that both compounds 406 and 401 not only delayed the onset of IL-6 release but also reduced the maximal amount of biologically active IL-6 secreted by PBMC as well as monocytes. Although a number of studies have reported the suppression of cytokine release and of the secretion of prostaglandin E2 and prostacyclin by lipid A partial structures as well as deacylated LPS in PBMC and vascular endothelial cells (27, 31, 36, 45) , the mechanism by which lipid A partial structures exert their inhibitory action is still not clear. Recently, it was reported that different LPS-binding sites that recognize different substructures or spatial configurations of the lipid A moiety of LPS are present on the surface of mouse macrophages (34, 39, 47) . At present, it is not possible to determine from our data whether the suppression of IL-6 release by lipid A partial structures is mediated through a competitive or a noncompatitive pathway. However, it should be noted that the inhibition of IL-6 release by treatment with compound 406 appears at an early stage. The release of IL-6 induced by BCG and S. aureus Cowan 1, which may use different pathways for inducing IL-6 release, was not influenced by the addition of compound 406 (Table  2) . These results agree well with the previous findings that Rhodobacter capsulatus LPS, which largely lacks cytokineinducing capacity, abolished the induction of IL-1 and TNF by other LPSs but did not alter the induction of cytokines by gram-positive Streptococcus epidermidis (33) . Furthermore, evidence provided by Kovach et al. (27) indicated that the specific inhibition by lipid A partial structure IVa (natural sources) of the accumulation of TNF mRNA and the release of TNF induced by Salmonella typhimurium LPS may be part of a competitive mechanism, perhaps at the receptor level. In favor of suppression via a specific mechanism, Riedo et al. (36) found that deacylated LPS could also specifically block a variety of endothelial cell responses to LPS, supporting the hypothesis that LPS partial structures and LPS interact with a common target molecule on or in endothelial cells. These data, together with those of our present investigations, strongly suggest that synthetic or naturally occurring poorly acylated LPS or lipid A partial structures are unable to mediate LPS-induced toxic reactions but can antagonize LPS-induced inflammatory reactions specifically by a competitive receptor-mediated phenomenon.
IFN--y, produced by T cells upon stimulation, has many immunomodulatory properties, including enhancement of LPS-induced IL-1 and TNF release by cultured macrophages (9) and augmentation of TNF cytotoxicity in vivo (41) . Recently, evidence indicating the pathophysiological role of IFN--y in the Shwartzman phenomenon and other endotoxin-related pathological phenomena has accumulated (23) . Elevated concentrations of IFN--y in serum have indeed been found in children with severe infectious purpura (18) and in adults with gram-negative septicemia (8) . It was reported that mice pretreated with IFN-y had dramatic increases in serum TNF during endotoxemia (21) . Pretreatment with an anti-IFN-y monoclonal antibody before LPS challenge significantly reduced the mortality of mice from endotoxic shock, indicating the direct involvement of IFN-y in the pathology of septic shock (21) . Because of the synergistic effects of IFN--y on LPS-mediated reactions in vitro as well as in vivo (9, 41), we performed experiments to investigate whether IFN--y could counteract the inhibitory effects of synthetic lipid A partial structures on LPS-or compound 506-induced IL-6 production. The results demonstrated that the synergism of LPS with IFN-y in the induction of IL-6 release from PBMC was significantly inhibited by the addition of synthetic lipid A partial structures at high concentrations in coincubation experiments. However, IFN--y still stimulated LPS-induced IL-6 release in the presence of low concentrations of compound 406 or 401 (Table 3) . On the basis of these results, we presume that IFN--y acts via a pathway which is independent of compound 406 or 401. Therefore, the antagonistic function of synthetic lipid A partial structures involves not only suppression of LPSmediated effects but also counteraction of the synergistic effects of IFN--y with LPS in the induction of IL-6.
Further work is required to resolve the detailed mechanism(s) of the suppressive action of synthetic lipid A partial structures on the molecular level as well as on the subpopulation of cells involved in the inhibition of IL-6 production. With regard to the inflammatory activities of IL-1, IL-6, IFN--y, and TNF produced during gram-negative infection, compounds 406 and 401 can be considered potent immunomodulators able to prevent the LPS-mediated production of these cytokines in vivo. Therefore, the use of these bacterial LPS antagonists may represent a new approach in the reduction of inflammatory reactions caused by systemic endotoxicosis.
